EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. ACN

Go back to EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
(NASDAQ: EYPT) Delayed: 4.56 -0.02 (0.44%)
Previous Close $4.58    52 Week High $ 
Open $4.58    52 Week Low $ 
Day High $4.69    P/E N/A 
Day Low $4.47    EPS $ 
Volume 2,270,628